[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647721":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":23,"locations":23,"responsibleParty":27,"collaborators":31,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":23,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":83,"whyStopped":23,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":23},{"fullName":5,"class":6},"Charite University, Berlin, Germany","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"NutriAct plus","Adults with obesity who have lost \\>= 7% of their body weight with semaglutide therapy over 3-5 months and who will follow NutriAct plus for 12 months",[12],"Behavioral: NutriAct plus",{"label":14,"type":6,"description":15,"interventionNames":16},"Rescue VLCD","Adults with obesity who have lost \\>= 7% of their body weight with semaglutide therapy over 3-5 months and who will receive rescue VLCD in case of weight regain for 12 months",[17],"Behavioral: Rescue VLCD",[19,24],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":23},"BEHAVIORAL","Dietary pattern, vegetarian version of the NutriAct pattern",[9],null,{"type":20,"name":14,"description":25,"armGroupLabels":26,"otherNames":23},"Very low calorie diet as full meal replacement over 28 days in case of weight regain",[14],{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"SPONSOR_INVESTIGATOR","Knut Mai","Prof. Dr.",[32,34,37,39,42,44,46,48,50,52,54],{"name":33,"class":6},"University of Latvia",{"name":35,"class":36},"Institute for Clinical and Experimental Medicine","OTHER_GOV",{"name":38,"class":6},"University of Vienna",{"name":40,"class":41},"ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)","UNKNOWN",{"name":43,"class":41},"Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DIfE)",{"name":45,"class":41},"German Federal Ministry of Research, Technology, and Space (BMFTR)",{"name":47,"class":6},"Austrian Science Fund (FWF)",{"name":49,"class":41},"Czech Health Research Council",{"name":51,"class":41},"Latvian Council of Science",{"name":53,"class":36},"Ministry of Health, Czech Republic",{"name":55,"class":41},"DLR Project Management Agency (DLR)","100647721","can-two-dietary-interventions-maintain-weight-loss-for-12-months-after-glp-1-therapy-in-adults-with-overweightobesity-100647721",false,"NCT07711548","Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight\u002FObesity?","DIETary Strategies to stabiLize Incretin-based Weight Loss in Obesity Management","DIET-SLIM","Inclusion Criteria:\n\n* BMI ≥ 30 kg\u002Fm² OR ≥ 27 kg\u002Fm² with concomitant cardiometabolic risk factors (metabolic syndrome, elevated blood pressure, dyslipidemia or impaired glucose metabolism (but not type 2 diabetes)\n\nExclusion Criteria:\n\n* BMI ≥ 45 kg\u002Fm²\n* intake of glucose lowering drugs\n* presence of incretin-based treatment\n* acute severe CVD\n* uncontrolled hypertension\n* severe hepatic or renal diseases\n* severe food allergy or malabsorption disease\n* active cancer\n* condition after bariatric surgery\n* history of eating disorder\n* concurrent pregnancy and breastfeeding","ALL","18 Years","70 Years",{"count":68,"type":69},292,"ESTIMATED","INTERVENTIONAL",[72],"NA","So far, treatment with semaglutide (Wegovy) for therapy of obesity demonstrates substantial effects. However, most patients do not desire life-long pharmaceutical therapy or discontinue this treatment regime. This is accompanied by rapid weight regain. Moreover, numerous patients are open to an intermittent therapy.\n\nThis trial aims to investigate whether two diet interventions can keep weight stable after weight loss with semaglutide in people with obesity or overweight.",[75,76],"Obesity & Overweight","Weight Loss Maintenance",[78,79,80,81,82],"Semaglutide","Obesity","Overweight","Diet","Weight loss maintenance","NOT_YET_RECRUITING","2026-07-17",{"date":86,"type":87},"2026-07-20","ACTUAL",{"date":89,"type":69},"2027-03",{"date":91,"type":69},"2030-04",{"name":29,"class":6}]